APPENDIX.
Disclosed Interests And Activities
| Name | Interest/Activity Type | Entity |
|---|---|---|
| Mary Beth Beasley, MD | Board or Advisory Board | Pulmonary Pathology Society Board of Trustees |
| Lecture fees paid by entity | International Association for the Study of Lung Cancer | |
| Expert witness | Willcox and Savage, Asbestos Litigation | |
| McGuire Woods, Cooch and Taylor, Asbestos Litigation | ||
| Cetrulo and Capone, Asbestos Litigation | ||
| Rassmussen, Dickey, Willis and Moore, Asbestos Litigation | ||
| Informa Health Care | ||
| Royalties | Lippincott, Williams & Wilkins | |
| Leadership in associations | Pulmonary Pathology Society, Secretary | |
| College of American Pathologists, Chair, Surgical Pathology Resource Committee | ||
| Philip T. Cagle, MD | Lecture fees paid by entity | Emory University |
| New York University | ||
| Oklahoma State Association of Pathologists | ||
| University of Michigan | ||
| Massachusetts General Hospital | ||
| Royalties | Springer Publishing | |
| Lippincott, Williams & Wilkins | ||
| Leadership in associations | Archives of Pathology & Laboratory Medicine, Editor-in-Chieff | |
| Texas Society of Pathologists, Chair of Education Council | ||
| Pulmonary Pathology Society, Past President | ||
| Pulmonary Pathology Society, Chair of Nominating Committee | ||
| Grants | Pennsylvania Breast Cancer Coalition | |
| Department of Defense | ||
| Dhananjay A. Chitale, MD | Susan G. Komen for the Cure | |
| National Institutes of Health | ||
| Consultancy | Novartis | |
| Lecture fees paid by entity | Millenium | |
| David J. Kwiatkowski, MD, PhD | Consultancy | Arqule/Daiichi Sankyo (April 2010) |
| NanoString (September 2012) | ||
| Marc Ladanyi, MD | Lecture fees paid by entity | Genzyme (March 2010) |
| Infinity (July 2010) | ||
| Sequenom (November 2009) | ||
| Remedica Medical Education (June 2012) | ||
| Family and business partners | Wife: Continuing medical education activities for Abbott | |
| Institutional financial interest | Memorial Sloan-Kettering Cancer Center licensed patent for EGFR T790M testing to MolecularMD. M.L. is not a patent holder. |
|
| Leadership in associations | Association for Molecular Pathology, Strategic Opportunities Committee | |
| United States and Canadian Academy of Pathology, Translational Genomics in Anatomic Pathology Task Force |
||
| American Association for Cancer Research, 2012 Annual Meeting Program Committee | ||
| Neal I. Lindeman, MD | Institutional financial interest | Partners Health Care has a patent on EGFR Mutation Testing. N.I.L. is not a patent holder. |
| Leadership in associations | Academy of Clinical Laboratory Physicians and Scientists, Paul E. Strandjord Young Investigator Award Coordinator |
|
| Association for Molecular Pathology, Solid Tumor Representative, Clinical Practices Committee |
||
| Association for Molecular Pathology, Nominating Committee, Solid Tumors Subdivision Representative |
||
| AACC, Nominating Committee, Molecular Division | ||
| AACC, Short Course/Interactive Workshops Director for AACC Annual Meeting Organizing Committee |
||
| College of American Pathologists, Molecular Oncology Resource Committee | ||
| Juan-Sebastian Saldivar, MD | Additional employment | Sequenom Center for Molecular Medicine |
| Existence Genetics | ||
| Institutional financial interest | City of Hope functions as a reference laboratory, providing somatic testing for NSCLC | |
| Jeremy A. Squire, PhD | Consultancy | CymoGen Dx, LLC |
| Board or Advisory Board | Applied Spectral Imaging | |
| Patents received or pending | Development of PTEN FISH Probe through Queens' University Commercialization Office (Parteq) |
|
| Royalties | Parteq-Queen's Commercialization Office | |
| Leadership in associations | NCIC (National Cancer Institute of Canada) Clinical Trials Group, Director of Laboratory Translational Research |
|
| Erik Thunnissen, MD. PhD | Board or Advisory Board | Merck |
| Eli Lilly | ||
| Pfizer | ||
| Lecture fees paid by entity | Merck | |
| Pfizer | ||
| Eli Lilly | ||
| Leadership in associations | European Society of Pathology lung external quality assessment | |
| Paul A. Bunn Jr, MD, Steering Committee |
Consultancy | Eli Lilly |
| OSI/Genentech/Roche | ||
| Astra Zeneca | ||
| Boehringer Ingelheim | ||
| Pfizer | ||
| Amgen | ||
| GlaxoSmithKline | ||
| Bristol-Myers-Squibb | ||
| Sanofi-Aventis | ||
| Board or Advisory Board | OSI/Genentech/Roche | |
| Astra Zeneca | ||
| Boehringer Ingelheim | ||
| Amgen | ||
| Bristol-Myers-Squibb | ||
| Sanofi-Aventis | ||
| Eli Lilly | ||
| Patents received or pending | Patent relating to use of EGFR FISH results as predictive biomarkers for EGFR therapy | |
| Employment | University of Colorado Denver | |
| International Association for the Study of Lung Cancer | ||
| Leadership in associations | International Association for the Study of Lung Cancer, Executive Director | |
| Jan A. Nowak, MD, Steering Committee |
Lecture fees paid by entity | William Beaumont Symposium |
| Employment | NorthShore University HealthSystem | |
| Leadership in associations | AMP, Past President 2010 | |
| AMP, Professional Relations Committee Member | ||
| AMP, Economic Affairs Committee Member |
Abbreviations: A ACC, American Association for Clinical Chemistry: AMP, Association for Molecular Pathology; EGFR, epidemial growth factor receptor; FISH, fluorescence in situ hybridization; NSCLC, non–small cell lung cancer; PTEN, phosphate and tensin homolog.
a
Dr. Cagle recused himself from the 3 journals' peer review process for this guideline, a process completed subsequent to the approval of the guideline by the 3 societies.